New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
16:07 EDTCTICCell Therapeutics sees FY13 loss from operations $60M-$65M
For 2013, loss from operations is expected to be approximately $60M-$65M, excluding non-cash stock-based compensation expense. The projected decrease in 2013 loss from operations, compared to 2012, primarily relates to expected changes in contribution margin from PIXUVRI commercial operations, as it intends to operate the commercial business with a net positive contribution; SG&A expenses, including sales and marketing expenses to drive sales of PIXUVRI; and R&D expenses.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:32 EDTCTICCTI BioPharma announces advancement of tosedostat LI-1 trial
Subscribe for More Information
November 23, 2015
09:18 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tyson Foods (TSN), up 2.4%... Mallinckrodt (MNK), up 7.4%. ALSO HIGHER: Novocure (NVCR), up 16.8% after announcing new Phase 3 data from Optune study... CTI BioPharma (CTIC), up 12.7% after the initiation of its rolling new drug application to the FDA for pacritinib... Peabody Energy (BTU), up 14.8% after announcing an asset sale... Sarepta Therapeutics (SRPT), up 5.2% following a positive mention in Barron's. DOWN AFTER EARNINGS: Trina Solar (TSL), down 5.6%. ALSO LOWER: Par Pacific (PARR), down 13.2% after pricing its 3.4M registered direct offering at $22.00... Lions Gate (LGF), down 2.9% after the "Hunger Games" finale opens below the series average.
05:39 EDTCTICCTI BioPharma initiates rolling submission of U.S. NDA for pacritinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use